

CASE REPORT

Open Access



The role of plasma metagenomic sequencing in identification of *Balamuthia mandrillaris* encephalitis

Sarah Y. Edminster^{1,2}, Ryan W. Rebbe^{1,2}, Christopher Khatchadourian^{1,2}, Kyle M. Hurth^{1,2}, Anna J. Mathew^{1,2}, Julie Huss-Bawab^{1,2}, Mark S. Shiroishi³, Devin Clark⁴, Andrew P. Norgan⁵, Susan M. Butler-Wu^{1,2} and Annie Hiniker^{1,2*}

Abstract

Balamuthia mandrillaris is a rare, free-living amoeba (FLA) that causes granulomatous amoebic encephalitis, a disease with close to 90% mortality. The geographical ranges of many FLA are expanding, potentially increasing human exposure to *B. mandrillaris*. Here, we report a case of a 58-year-old woman with progressive neurological symptoms, ultimately diagnosed postmortem with *B. mandrillaris* encephalitis through plasma metagenomic next-generation sequencing (mNGS) despite negative results on both cerebrospinal fluid (CSF) mNGS and CSF PCR testing. Histologic analysis and real-time PCR (qPCR) studies on postmortem brain tissue confirmed *B. mandrillaris* infection with significant vascular clustering of trophozoites. Retrospective analysis of CSF mNGS data demonstrated subthreshold reads for *B. mandrillaris*, emphasizing the challenges of interpreting low-level pathogen signals. A systematic review of 159 published *B. mandrillaris* cases revealed only two reports of *B. mandrillaris* diagnosed using plasma mNGS, both of which also had diagnostic CSF studies. This case demonstrates the diagnostic challenges of *B. mandrillaris* infections, highlights its vascular tropism, and suggests that plasma mNGS may warrant evaluation as a diagnostic tool for *B. mandrillaris*.

Keywords *Balamuthia*, *Balamuthia mandrillaris*, Amoeba, Amoebic encephalitis, Plasma metagenomic sequencing, Free living amoeba, Granulomatous amoebic encephalitis

Introduction

Balamuthia mandrillaris is a free-living amoeba (FLA) that causes granulomatous amoebic encephalitis (GAE), a rare and highly fatal condition characterized pathologically by variable degrees of inflammation, granuloma formation, and tissue necrosis. Found in soil and water, *B. mandrillaris* infections typically arise from direct inoculation through skin wounds or inhalation [11]. GAE often presents with nonspecific neurological symptoms, including headache, fever, and focal deficits, which complicates diagnosis and can delay treatment [11]. Accurate diagnosis requires differentiation from *Acanthamoeba spp.*, another cause of GAE.

*Correspondence:

Annie Hiniker
ahnicker@usc.edu; ahnicker@dhs.lacounty.gov

¹ Department of Pathology, Los Angeles General Medical Center, Los Angeles, CA 90033, USA

² Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA

³ Department of Neuroradiology, Los Angeles Medical Center, Los Angeles, CA 90033, USA

⁴ Department of Infectious Diseases, Los Angeles General Medical Center, Los Angeles, CA 90033, USA

⁵ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA



The increasing prevalence of amoebic infections over recent decades has been associated with climate change [27], suggesting that the need for diagnostic tools for *B. mandrillaris* may increase. Traditional diagnostic methods such as cerebrospinal fluid (CSF) analysis and neuroimaging frequently fail to identify *B. mandrillaris* [92]. Recent advances in metagenomic next-generation sequencing (mNGS) have augmented diagnosis of many central nervous system infections [25, 29, 36, 104]. mNGS sequences all nucleic acids present in a sample at very high depth, allowing unbiased pathogen detection from diverse tissue samples [25, 29, 36, 104]. While mNGS has been applied successfully to CSF and brain tissue in many GAE cases, the diagnostic utility of plasma mNGS in GAE has not been comprehensively evaluated.

Here, we report a fatal case of *B. mandrillaris* GAE diagnosed via plasma mNGS, despite negative CSF mNGS results. Retrospective analysis of CSF mNGS revealed subthreshold reads for *B. mandrillaris*, emphasizing the challenges of interpreting low-level pathogen signals. This case and our review of the literature highlight the organism's pronounced vascular tropism, which we hypothesize could underlie a potential utility for plasma mNGS as a diagnostic tool for GAE.

Case presentation

A 58-year-old woman, with no significant past medical history, presented with 10 days of progressive neurological symptoms, including right facial numbness, left-sided hemiparesis, imbalance, and tinnitus. She presented with no visible skin lesions; however, she reported having sustained superficial scratches on her arms from gardening several weeks prior, which had resolved. Upon examination, no skin lesions were observed. Brain MRI revealed a 2.1 cm rim-enhancing lesion in the right pons with surrounding edema and mass effect (Fig. 1a). CSF analysis showed lymphocytic pleocytosis (132–203 cells/

μL), increased opening pressure (27 cm H₂O), elevated protein (64 mg/dL), and normal glucose levels. Comprehensive testing for bacterial, fungal, mycobacterial, viral, and autoimmune etiologies yielded negative results (see Table 1). Flow cytometry indicated reactive T-cells without aberrancy.

A biopsy of the right middle cerebellar peduncle showed chronic inflammation with macrophage infiltration (CD68-positive) and necrosis, without identifiable organisms and with rare possible granulomas (Fig. 1b–d). Stains for acid-fast bacilli (AFB), fungal organisms (GMS), Gram-positive/negative bacteria, and other pathogens were negative. Cultures of blood, CSF, and biopsy tissue—including anaerobic, fungal, and mycobacterial screens—were negative. Despite broad-spectrum antimicrobials and methylprednisolone for suspected demyelination, the patient's condition deteriorated.

Follow up MRI, performed 28 days after the initial scan, demonstrated expansion of the initial lesion with new brainstem, cerebellar, cerebral, and leptomeningeal lesions (Fig. 2a–c), and multifocal vessel wall enhancement of the bilateral middle cerebral, internal carotid, and vertebral arteries (Fig. 4a–d). Cyclophosphamide was initiated for suspected primary CNS angiitis. Biopsies of the dura and cerebellum showed only chronic inflammation. mNGS of CSF was not reported to be positive for any organisms. The patient's disease progressed to status epilepticus, obstructive hydrocephalus, brainstem herniation, and death. Plasma mNGS, ordered prior to the patient's death, identified *B. mandrillaris* postmortem.

Autopsy revealed severe cerebral edema, cerebellar herniation, hemorrhage, and necrosis of the occipital lobes, brainstem, and cerebellum (Fig. 2d). Histopathological evaluation demonstrated trophozoites and cysts in necrotic brain tissue and perivascular spaces (Fig. 3a–c). There was marked perivascular inflammation with fibrinoid necrosis of vasculature (Fig. 4e).




Fig. 1 Initial MRI and surgical biopsy. **a** Initial axial post-contrast T1-weighted MRI, performed the day after admission, showed a right pontine rim-enhancing lesion (arrow). Right middle cerebellar peduncle biopsy demonstrated **b** macrophage-rich chronic inflammation (H&E, 20x) with **c** CD68 stain highlighting numerous macrophages (CD68, 20x). **d** Rare possible granulomas were identified (H&E, 40x). Scale bars: b, c=50 μm , d=20 μm

Table 1 Laboratory test results

Test type	Test name	Result
Culture	Aerobic & Anaerobic	No growth
	AFB	No growth
Serology	Interferon-gamma Release Assay	Non-reactive
	HIV Ab/Ag screen	Non-reactive
	RPR Qualitative	Non-reactive
	Toxoplasmosis Ab IgG/IgM	Not Detected
	Aspergillus Ab	Not Detected
	CNS Demyelination Ab Panel	No Informative Antibodies Identified
	ANCA Ab	Not Detected
PCR	Sjogren Ab	Not Detected
	<i>E. coli</i> K1	Not Detected
	<i>H. influenzae</i>	Not Detected
	<i>L. monocytogenes</i>	Not Detected
	<i>N. meningitidis</i>	Not Detected
	<i>S. agalactiae</i>	Not Detected
	<i>S. pneumoniae</i>	Not Detected
	CMV	Not Detected
	HSV-1	Not Detected
	HSV-2	Not Detected
	VZV	Not Detected
	EBV	Not Detected
	HSV-6	Not Detected
	HPeV	Not Detected
Other	<i>C. neoformans/gattii</i>	Not Detected
	Coccidioides Ab	Not Detected
	CSF Cytology & Chemistry	Colorless & Clear, > 200 cells/mm ³ , PMN 11%, Plasma 2%, Nucleated cell count 2%, Lymph 85%, Mono 60 mg/dL, Protein 64 mg/dL
	Flow Cytometry	No Abnormal T-cell Population
	Oligoclonal Bands	Absent

The trophozoites, many of which were necrotic, were round to ovoid with foamy cytoplasm; most had a single, round nucleus (Fig. 3b). The cyst forms appeared to show varying stages of development, with mature cysts characterized by thick, multilayered capsules enclosing vacuolated cytoplasm, and a nucleus (Fig. 3c). Prominent perivascular clustering of trophozoites and vascular invasion were observed, primarily by cyst forms (Figs. 4f and 5). Giemsa (Figs. 3a, 5d) and PAS (Fig. 5a and b) stains highlighted amoebae. Targeted qPCR on formalin-fixed paraffin-embedded (FFPE) brain tissue confirmed *B. mandrillaris* DNA in the brainstem and cerebellum (Fig. 3d). Retrospective analysis of CSF mNGS revealed subthreshold reads for *B. mandrillaris*. PCR for *B. mandrillaris* on this CSF sample was negative.

Discussion and conclusions

GAE is a rare but often fatal infection caused by free-living amoebae (FLA) such as *Acanthamoeba spp.* and *B. mandrillaris* (previously known as “leptomyxid ameba”) [8]. Our autopsy findings included striking perivascular clustering of amoebae and vascular invasion (Figs. 4, 5). The organism’s ability to cross the blood–brain barrier involves interactions with human brain microvascular endothelial cells (HBMECs) via carbohydrate moieties, facilitating CNS invasion [53]. This vascular affinity likely contributed to the multifocal vessel wall enhancement observed on imaging (Fig. 4a–d). We hypothesized that these characteristics facilitated the detectability of circulating trophozoites or DNA fragments in plasma, leading to the positive plasma mNGS result in this case.




Fig. 2 Follow-up MRI findings and gross brain at postmortem examination. Axial post-contrast T1-weighted MRI performed on day 29 of hospitalization showed **a** expansion of the initial pontine lesion (arrow) with **b** new brainstem (arrow) and cerebellar lesions (arrows) as well as **c** cerebral (white arrow) and leptomeningeal (red arrows) lesions. **d** Brain at autopsy with cerebral edema, cerebellar herniation, hemorrhage, and brainstem necrosis (arrow)

To further investigate diagnostic testing regimens and vascular association of *B. mandrillaris*, we performed a PubMed review with key words “*Balamuthia mandrillaris*” or “*leptomyxid amoeba*” and identified 159 unique published cases of *B. mandrillaris* infection that had clear CNS or skin involvement and also reported patient demographics, outcome, and diagnostic methods (Table 2). This revealed 120 cases of *B. mandrillaris* diagnosed in brain tissue, 18 in skin, and 30 in CSF, with some cases diagnosed at more than one site. There was a high mortality rate of approximately 89%. The average patient age was 36 years, with cases spanning all age groups: children (< 18 years, 59 cases), adults (18–64 years, 72 cases), and older adults (65+ years, 28 cases). Gender distribution included 100 males and 58 females. One case lacked gender information. Within the United States, cases were geographically widespread, with the highest concentrations reported in Texas and California. Notably, the vascular tropism of *B. mandrillaris* observed in our case aligned with many prior studies. We identified both in vitro evidence for a predilection for perivascular invasion and vascular inflammation [53] as well as at least 10 cases with explicit mention of perivascular or vascular involvement on neuropathologic tissue analysis [24, 32, 33, 50, 56, 79, 81, 120–122].




Fig. 3 *B. mandrillaris* trophozoites and cysts, and free-living amoeba PCR. **a** Trophozoites adjacent to cerebellar granule cells (Giemsa, 40x). High-power views of **b** trophozoites (H&E, 100x) and **c** cysts (H&E, 100x). **d** PCR amplification curves of *B. mandrillaris* specific nucleic acid in: (A) *B. mandrillaris* positive control ($C_p = 28.3$) and (B) patient's cerebellar FFPE tissue ($C_p = 31$). (C) negative controls (*Naegleria fowleri* and Vero cell line controls). Scale bars: a = 200 μ m; b, c = 10 μ m

First identified in 1989 in a pregnant mandrill baboon at the San Diego Zoo Safari Park through use of immunofluorescence assay (IFA) [87], *B. mandrillaris* was retrospectively identified in human cases dating back to 1974 [87]. Since then, diagnostic modalities have evolved and include immunohistochemistry, immunofluorescence, and molecular techniques such as PCR, qPCR, RT-PCR, Sanger sequencing, and enzyme-linked immunosorbent assay. These tools have been applied to various specimens, including FFPE tissue, amoebic cultures, blood, and CSF, with varying success. While PCR is a cornerstone of infectious disease diagnostics, its sensitivity for *B. mandrillaris* remains suboptimal, with reported detection rates as low as 6%, underscoring the limitations of traditional diagnostic methods [11].

In recent years, mNGS has emerged as a potential diagnostic tool for *B. mandrillaris* and has been applied to specimens including brain tissue, CSF, and, recently,




Fig. 4 Vessel wall enhancement on antemortem MRI and H&E stain of postmortem brain. Axial post-contrast T1-weighted MRI performed on day 29 of hospitalization showed vessel abnormalities, including **a** bilateral middle cerebral artery (MCA) and **b** bilateral internal carotid artery (ICA) wall enhancement (arrows). **c** and **d** provide closer views of vessel wall enhancement (arrows; brightness/contrast of image adjusted for visualization). **e** Fibrinoid necrosis of the vasculature (arrow, H&E, 20x). **f** Perivascular trophozoites in the cerebellum (arrow, H&E, 40x). Scale bars: e=50 μ m, f=20 μ m




Fig. 5 Vascular tropism of *B. mandrillaris* observed at postmortem brain examination. **a–b** Perivascular trophozoites in the cerebellum (arrows) (PAS; a: 20x, b: 40x). **c–e** Invasion of the arterial wall, predominantly by cysts (c: H&E, 10x; d: Giemsa, 40x; e: H&E, 100x). Scale bars: a=50 μ m, b, d=20 μ m, c=100 μ m, e 10 μ m

Table 2 A systematic review of 159 reported cases of *B. mandrillaris* infection: demographics, initial presentation, outcome, and diagnostic methods

Publication [References #]	Demographics (age in years, gender)	Clinical presentation	Outcome	Method of diagnosis	Diagnosed by plasma mNGS
Our case	58 F	Progressive facial numbness, hemiparesis, imbalance, and tinnitus	Deceased	mNGS (plasma), qPCR (brain), negative on PCR & mNGS (CSF)	Yes
Aboubechara et al. (2024) [120]	4 F	Facial droop, dysarthria, hemiparesis, upper respiratory tract symptoms, headache, fever	Deceased	mNGS (plasma), PCR (CSF)	Yes
Xiong et al. (2024) [119]	35 M	Fever, limb convulsions, progressive quadripareis	Deceased	mNGS (brain)	No
Wang et al. (2024) [90]	49 F	Headache, dizziness, nausea, emesis, prior skin lesion(s)	Deceased	mNGS (brain)	No
Zheng et al. (2024) [102]	58 M	Headache, fever	Deceased	mNGS (CSF)	No
Szymanski et al. (2024) [80]	3 M	Fatigue and facial pain, previously healthy with baseline facial palsy with right lip droop	Deceased	Not specified	Not specified
Javed et al. (2024) [33]	33 F	Back pain, headache, emesis	Deceased	PCR & Sanger sequencing (specimen not specified)	No
Qin et al. (2024) [66]	47 M	Fever following allogenic renal transplant	Not specified	mNGS (specimen not specified)	Not specified
Xu et al. (2024) [94]	66 F	Headache	Deceased	mNGS (CSF)	No
Qin et al. (2024) [65]	52 M	Headache, difficulty walking, blunted affect	Deceased	mNGS (CSF), PCR (CSF)	No
Li et al. (2024) [46]	77 F	Dizziness, unsteady gait	Deceased	mNGS (CSF)	No
Ono et al. (2023) [56]	76 F	Headache, nausea	Deceased	PCR (brain), negative PCR (CSF)	No
Gramp et al. (2023) [24]	66 M	Skin lesion(s)	Deceased	PCR (skin & brain)	No
Yao et al. (2023) [97]	64 F	Headache, abdominal pain, dizziness, unsteady gait, cough, emesis, prior skin lesion(s)	Deceased	mNGS (CSF), PCR (CSF), qRT-PCR (CSF)	No
Spottiswoode et al. (2023) [105]	50s M	Seizure	Survived	mNGS (brain) & Sanger sequencing (brain), negative mNGS (CSF) & PCR(CSF)	No
Liu et al. (2023) [47]	61 M	Headache	Deceased	mNGS (CSF)	No
Sakusic et al. (2023) [71]	61 F	Headache, prior orthotopic heart transplant	Deceased	Broad-range PCR sequencing (brain)	No
Fan et al. (2023) [20]	56 M	Transient coma, nausea, emesis	Deceased	mNGS (CSF)	No
Xu et al. (2022) [108]	54 M	Headache, dizziness, skin lesion(s)	Deceased	mNGS (CSF)	No
Saffotti et al. (2022) [109]	17 M	Headache, weight loss, swollen nose	Deceased	qPCR (brain)	No
Levinson et al. (2022) [106]	80 M	Altered mental status, dizziness, vision loss	Survived	Multiplex RT-qPCR (CSF & brain)	No
Toitla et al. (2022) [85]	3(?)	Skin lesion(s)	Deceased	PCR (skin) with bidirectional Sanger sequencing	No
Wang et al. (2022) [89]	14 M	Skin lesion(s)	Survived	IHC (skin)	No
Wang et al. (2022) [89]	57 F	Skin lesion(s)	Deceased	IHC (skin)	No
Wang et al. (2022) [89]	9 M	Skin lesion(s)	Survived	IHC (skin)	No
Maehara et al. (2022) [50]	82 M	Amnesia, skin lesion(s)	Deceased	IHC (skin & brain), PCR and sequencing (skin & brain)	No
Zhang et al. (2021) [101]	7 M	Skin lesion(s)	Deceased	IHC (skin), PCR (skin), negative NGS (skin)	No

Table 2 (continued)

Publication [References #]	Demographics (age in years, gender)	Clinical presentation	Outcome	Method of diagnosis	Diagnosed by plasma mNGS
Cuoco et al. (2022) [14]	4 M	Seizure	Survived	multiplex RT-qPCR (brain)	No
Peng et al. (2022) [59]	54 M	Numbness and weakness of extremity	Survived	mNGS (CSF, brain, & serum)	No (serum)
Hu et al. (2022) [30]	37 F	Dizziness, skin lesion(s)	Deceased	mNGS (CSF)	No
Ai et al. (2022) [11]	15 M	Fever, altered mental status; previous skin lesion(s)	Deceased	mNGS (CSF), PCR (skin)	No
Hirakata et al. (2021) [29]	60 F	Homonymous hemianopsia	Deceased	mNGS (brain), PCR (brain & skin)	No
Kalyatanda (2020) [36]	51 M	Seizure, headache, altered mental status, disorientation, left-sided weakness, night sweats, diarrhea	Deceased	mNGS (plasma), multiplex qPCR (CSF), IHC (brain)	Yes
Yi et al. (2020) [98]	9 F	Emesis, loss of appetite, fever, headache, difficulty walking, blurred vision, altered mental status	Deceased	mNGS (CSF)	No
Mani et al. (2021) [51]	51 M	Blurry vision, headache, imbalance, altered mental status	Deceased	Multiplex qPCR (CSF)	No
Lee et al. (2021) [44]	50 M	Headache, dizziness, dysarthria, aphasia	Deceased	qPCR (brain)	No
Zwillman et al. (2021) [103]	65 M	Weakness, lethargy, lower extremity cellulitis, fever, encephalopathy	Deceased	qPCR (brain), IHC (brain)	No
Suyo-Prieto et al. (2020) [78]	21 M	Seizure, skin lesion(s), nausea, headache	Deceased	PCR and sequencing (skin)	No
Safavi et al. (2021) [70]	3 F	Altered mental status, emesis, dizziness, seizure, hemiparesis, ataxia	Deceased	PCR (brain)	No
Wu et al. (2020) [93]	13 F	Dizziness, emesis, and blurry vision, prior skin lesion(s)	Deceased	NGS (CSF), PCR (skin), immunostaining (serum & CSF)	No
Aoki et al. (2020) [3]	63 F	Dyspnea and left recurrent nerve paralysis	Deceased	PCR (brain), IHC (brain)	No
Pan et al. (2020) [58]	85 F	Confusion, weakness, slurred speech	Deceased	qPCR (brain), PCR (brain)	No
Yang et al. (2020) [96]	2 M	Fever	Deceased	NGS (CSF)	No
Suzuki et al. (2020) [79]	68 M	Seizures, transient right hemiparesis	Deceased	IHC (brain), PCR (brain)	No
Lee et al. (2020) [43]	45 M	Seizure	Deceased	qPCR (brain)	No
Kum et al. (2019) [110]	71 M	Muscle spasms	Deceased	Diagnosed based on histomorphology of brain tissue, no confirmatory testing	No
Yohannan et al. (2019) [99]	69 F	Altered mental status	Deceased	qPCR (brain), IHC (brain)	No
Hara et al. (2019) [116]	56 M	Seizure, hemiparesis, fever, altered level of consciousness	Deceased	IHC (brain)	No
Hara et al. (2019) [116]	72 F	Lightheadedness, fever	Deceased	IHC (brain)	No
Hara et al. (2019) [116]	53 M	Headache, fever	Deceased	IHC (brain)	No
Hara et al. (2019) [116]	56 F	Fever, malaise	Deceased	IHC (brain)	No

Table 2 (continued)

Publication [References #]	Demographics (age in years, gender)	Clinical presentation	Outcome	Method of diagnosis	Diagnosed by plasma mNGS
Hara et al. (2019) [116]	69 M	Altered level of consciousness	Deceased	IHC (brain)	No
Hara et al. (2019) [116]	72 M	Loss of appetite, cognitive decline	Deceased	CSF microscopy, no confirmatory testing	No
Hara et al. (2019) [116]	79 M	Skin lesion(s)	Deceased	IHC (brain), PCR (brain)	No
Hara et al. (2019) [116]	67 F	Diplopia, lightheadedness	Deceased	Not specified	No
Hara et al. (2019) [116]	61 F	Homonymous hemianopsia	Deceased	Whole genome sequencing (brain), PCR (brain), and IHC (brain)	No
Hara et al. (2019) [116]	55 M	Unknown	Deceased	IHC (brain), PCR (brain)	No
Piper et al. (2018) [62]	69 F	Skin lesion(s), seizures, prior chronic sinus infection	Deceased	qPCR (skin & brain), IFA (serum)	No
Tatjai et al. (2018) [82]	57 M	Altered mental status, seizures	Deceased	PCR (brain)	No
Shehab et al. (2018) [112]	13 F	Hemiparesis, slurred speech	Deceased	Diagnosed based on histomorphology of brain tissue, no confirmatory testing	No
Joo et al. (2018) [34]	6 M	Headache, fever, emesis	Deceased	qPCR (CSF)	No
Takei et al. (2018) [81]	74 F	Somnolence	Deceased	IHC (brain), negative PCR (CSF, brain)	No
Cope et al. (2018) [12]	18 F	Headache, fever, lethargy	Deceased	qPCR (CSF)	No
Lehmer et al. (2017) [111]	84 M	Skin lesion(s)	Survived	IFA (brain & skin)	No
Mittal et al. (2017) [54]	32 M	Seizure	Not specified	IFA and PCR (specimen not specified)	No
Chang et al. (2016) [9]	91 F	Skin lesion(s)	Survived	IHC (skin), PCR (skin)	No
Völlmer et al. (2016) [88]	26 M	Visual disturbances, lightheadedness, headache, syncope	Survived	IFA (brain), PCR (brain)	No
Kobayashi et al. (2015) [40]	57 F	Headache	Deceased	IHC (brain), PCR (brain)	No
Ott et al. (2015) [113]	41 M	Encephalitis symptoms	Deceased	PCR (specimen not specified)	No
Roy et al. (2015) [69]	11 M	Nausea, emesis, lethargy, clumsiness, and right-sided weakness	Deceased	IFA (brain, lung), qPCR (brain, CSF), Sanger sequencing (brain, CSF), PCR (brain, CSF) Sanger sequencing (brain, CSF), serology, IHC (brain)	No
Wilson et al. (2015) [92]	74 F	Altered mental status, fever	Deceased	mNGS (CSF), PCR (brain, CSF) Sanger sequencing (brain, CSF), serology, IHC (brain)	No
Schäfer et al. (2015) [72]	82 M	Fever, chills, nausea, emesis, lethargy, altered mental status, prior skin lesion(s)	Deceased	qPCR (brain), IFA (skin)	No
van der Beek et al. (2015) [86]	61 F	Fever, headaches, myalgias, prior skin lesions	Deceased	qPCR (brain, CSF) with sequencing	No
Khurana et al. (2015) [39]	18 M	Headache, emesis, limb weakness, slurred speech, fever, altered mental status	Deceased	PCR (brain)	No
Khurana et al. (2015) [39]	18 M	Headache, diplopia, fever, emesis	Deceased	PCR (brain) with sequencing	No
Grenninger et al. (2015) [115]	15 F	Limb weakness, headache, emesis, ataxia, confusion	Deceased	mNGS (CSF, brain), PCR (brain)	No
Itch et al. (2015) [32]	81 M	Somnolence, disoriented, ataxic gait	Deceased	PCR (brain), IHC (brain)	No

Table 2 (continued)

Publication [References #]	Demographics (age in years, gender)	Clinical presentation	Outcome	Method of diagnosis	Diagnosed by plasma mNGS
Pinsky et al. (2014) [14] Lobo et al. (2013) [48]	56 M 48 F	Fever, hyponatremia Headache, neck pain, fever, diplopia, slurred speech, fever Headache, numbness, tingling	Deceased Deceased	IHC (brain), PCR (specimen not specified) IFA (brain, serum)	No No
Phillips et al. (2013) [61] Kraselap et al. (2013) [42]	59 M 4 F	Headache, emesis Headache, abnormal gait, seizures	Deceased Deceased	PCR (brain) PCR with sequencing (brain & CSF)	No No
Moriarty et al. (2013) [117] Moriarty et al. (2013) [117] Kato et al. (2013) [118]	4 F 11 F 72 M	Fever, headache, meningismus Somnolence, altered level of consciousness, hemiparesis	Survived Deceased Survived	PCR (brain), serology and IFA (brain) IFA (brain), PCR (brain) Diagnosed based on CSF morphology, negative PCR (CSF) & IFA (brain)	No No No
Studd et al. (2012) [77]	2 F	Initial fall followed by recurrent falls, ataxia, irritability, lethargy, photophobia, fever	Deceased	qPCR (brain), IFA (brain)	No
Hill et al. (2011) [28] Doyle et al. (2010) [18]	0 y 8 mo F 80 F	Lethargy, irritability, seizures, weakness Skin lesion(s)	Deceased Survived	IFA (brain) PCR (brain & skin)	No No
Yamasaki et al. (2011) [95] Silva et al. (2010) [75]	51 F 47 F	Seizure Headache	Deceased Deceased	IHC (brain), ELISA (brain) IHC (brain), PCR (brain)	No No
Centers for Disease Control and Prevention (CDC) (2010) [7] Centers for Disease Control and Prevention (CDC) (2010) [7]	27 M	Organ donor, presented with presumed stroke, prior skin lesions(s)	Deceased	Not specified	No
Centers for Disease Control and Prevention (CDC) (2010) [7]	56 M	Liver transplant recipient, presented with diplopia and difficulty walking	Deceased	qPCR (brain), IHC (brain & liver)	No
Centers for Disease Control and Prevention (CDC) (2010) [7]	24 M	Kidney and pancreas transplant recipient, presented with headache, nausea, emesis	Deceased	qPCR (brain), IHC (brain)	No
Centers for Disease Control and Prevention (CDC) (2010) [6]	4 M	Organ donor, presented with fever, personality changes, loss of appetite, muscle twitching, headache, seizure	Deceased	IHC (brain), IFA (brain), PCR (brain)	No
Centers for Disease Control and Prevention (CDC) (2010) [6]	31 F	Kidney transplant recipient, presented with paresthesias, muscle spasms, headache, nausea, altered mental status, seizure	Deceased	PCR (brain)	No
Centers for Disease Control and Prevention (CDC) (2010) [6]	27 M	Kidney transplant recipient, presented with headache, nausea, altered mental status, seizure	Survived	PCR (CSF)	No
Cary et al. (2010) [5] Kansagra et al. (2009) [37] Prasad et al. (2008) [107]	2 M 43 M 22 M	Vomiting and diarrhea Fever, headache, and nausea Numbness, vertigo, difficulty swallowing, weakness, seizure, chronic suppurative otitis media	Survived Deceased Deceased	IFA (brain) IFA (brain) PCR (brain)	No No No
Silva-Vergara et al. (2007) [76]	32 M	Headache, blurred vision, and fever	Deceased	IFA (brain)	No

Table 2 (continued)

Publication [References #]	Demographics (age in years, gender)	Clinical presentation	Outcome	Method of diagnosis	Diagnosed by plasma mNGS
Perez et al. (2007) [60] Cuevas et al. (2006) [13]	40 M 5 F	Seizure Skin lesion(s)	Deceased Deceased	IFA (brain) Diagnosed based on histomorphology of brain tissue, no confirmatory testing	No No
Tavares et al. (2006) [84]	8 M	Headache, medial esotropia, diplopia, signs of intracranial hypertension	Deceased	IFA (brain), PCR (brain)	No
Li et al. (2005) [45] White et al. (2004) [91]	6 F 32 M	Headache and stiff neck Confusion and focal neurological signs, prior skin lesion(s)	Deceased Deceased	IFA (brain) IFA (serum)	No No
Intalaporn et al. (2004) [31] Jung et al. (2004) [35]	23 M 72 F	Skin lesion(s) Seizure, visual loss, aphasia	Deceased Survived	IFA (brain) IFA (brain)	No No
Prtzker et al. (2004) [64]	89 M	Skin lesion(s)	Deceased	IFA (skin)	No
Deeert et al. (2003) [15] Deeert et al. (2003) [15]	64 M 5 F	Hemiparesis, speech difficulty, seizure Seizure, fever	Survived Survived	IFA (brain) IFA (brain)	No No
Bakardjiev et al. (2003) [4] & Schuster et al. (2003) [73]	3 F	Fever, fatigue, otitis media, dehydration, seizure, emesis	Deceased	IFA (serum, brain), PCR (brain), with sequencing	No
Bakardjiev et al. (2003) [4]	2 F	Fever, headache, lateral eye deviation, facial palsy, hemiparesis, otitis media	Deceased	IFA (brain)	No
Bakardjiev et al. (2003) [4]	7 M	Fever, chills, seizure, wide based gait, cranial nerve palsy (V), abdominal pain/personality change	Deceased	Elevated serum titers	No
Bakardjiev et al. (2003) [4] Shirabe et al. (2002) [74]	2.5 M 78 F	Fever, emesis, ataxia Fever	Deceased Deceased	IFA (brain), titers (serum, CSF) IFA (brain)	No No
Galarza et al. (2002) [21] Galarza et al. (2002) [21]	12 M	Skin lesion(s)	Deceased	IFA (brain)	No
Galarza et al. (2002) [21] Galarza et al. (2002) [21]	5 M 3 F	Skin lesion(s), seizure, loss of consciousness Seizure, loss of consciousness, hemiparesis	Deceased Deceased	IFA (brain) IFA (brain)	No No
Galarza et al. (2002) [21]	6 M	Skin lesion(s), hemiparesis, loss of consciousness	Deceased	IFA (brain)	No
Katz et al. (2000) [38] Deol et al. (2000) [17]	52 F 38 M	Seizure, prior skin lesion(s) Skin lesion(s), weight loss, seizures	Deceased Deceased	IFA (brain) IFA (brain)	No No
Recavarren-Aice et al. (1999) [122] Recavarren-Aice et al. (1999) [122]	22 M	Skin lesion(s), neurological symptoms	Deceased	IFA (brain)	No
Recavarren-Aice et al. (1999) [122] Recavarren-Aice et al. (1999) [122]	5 M 9 M	Skin lesion(s), neurological symptoms	Deceased	IFA (brain)	No
Recavarren-Aice et al. (1999) [122] Recavarren-Aice et al. (1999) [122]	10 M	Skin lesion(s), neurological symptoms	Deceased	IFA (brain)	No
Recavarren-Aice et al. (1999) [122] Recavarren-Aice et al. (1999) [122]	12 M 50 F	Skin lesion(s), neurological symptoms Skin lesion(s), neurological symptoms	Deceased Deceased	IFA (brain) IFA (brain)	No No

Table 2 (continued)

Publication [References #]	Demographics (age in years, gender)	Clinical presentation	Outcome	Method of diagnosis	Diagnosed by plasma mNGS
Recavarren-Aice et al. (1999) [12]	34 M	Skin lesion(s), neurological symptoms	Deceased	IFA (brain)	No
Recavarren-Aice et al. (1999) [12]	14 M	Skin lesion(s), neurological symptoms	Deceased	IFA (brain)	No
Recavarren-Aice et al. (1999) [12]	28 M	Skin lesion(s), neurological symptoms	Deceased	IFA (brain)	No
Koder et al. (1998) [41]	3 M	Lethargy, seizure	Deceased	IFA (brain)	No
Denney et al. (1997) [16]	32 M	Nausea, emesis, headache	Deceased	IFA (brain)	No
Reed et al. (1997) [67]	5 M	Skin lesion(s)	Deceased	IFA (brain)	No
Duke et al. (1997) [19]	3 M	Pharyngitis, fever, chills, emesis, irritability, somnolence	Deceased	Not specified	No
Rowen et al. (1995) [68]	5 M	Extremity weakness, slurred speech	Deceased	IFA (brain)	No
Rowen et al. (1995) [68]	15 M	Headache, emesis, abdominal pain	Deceased	IFA (brain)	No
Martinez et al. (1994) [52]	14 M	Seizure, limb weakness, headache	Deceased	IFA (brain)	No
Zagardo et al. (1997) [100]	34 F	Seizure, fever, cranial nerve palsy, pronator drift	Deceased	IFA (brain)	No
Lowichik et al. (1995) [49]	0 y 11 mo F	Internal strabismus, unsteady crawling, difficulty grasping objects, cranial nerve palsy	Deceased	IFA (brain)	No
Griesemer et al. (1994) [26]	2 M	Otitis media, hemiparesis, aphasia, emesis, lethargy, fever, instability	Deceased	IFA (brain)	No
Griesemer et al. (1994) [26]	13 F	Headache, diplopia, hemiparesis, left facial weakness, emesis	Deceased	IFA (brain)	No
Neafie et al. (1993) [55]	1 M	Hemiplegia, lethargy	Deceased	IFA (brain)	No
Gordon et al. (1992) [23]	52 M	Skin lesion(s), headache, fever, chills	Deceased	IFA (brain & skin)	No
Popek et al. (1992) [63]	0 y 5 mo F	Sore throat, otitis media, seizures, fever	Deceased	IFA (brain)	No
Chimelli et al. (1992) [10]	47 F	Weakness, myalgia, fever, weight loss, headache	Deceased	IFA (brain)	No
González-Alfonzo et al. (1991) [22]	7 M	Pain, swelling, serous eye discharge	Deceased	IFA (brain)	No
Tarafuto et al. (1991) [83]	12 M	Skin lesion(s), hyperthermia, headache, conjugate gaze deviation, facial palsy, dysarthria, hemiparesis	Deceased	IFA (brain)	No
Anzil et al. (1991) [2]	36 M	Headache, fever	Deceased	IFA (brain)	No
Visvesvara et al. (1990) [87]	2 F	Headache	Deceased	IFA (brain)	No
Visvesvara et al. (1990) [87]	0 y 3 mo M	Diarrhea, dehydration, fever, pneumonia	Deceased	IFA (brain)	No
Visvesvara et al. (1990) [87]	2.5 M	Neurologic dysfunction, headache, emesis	Deceased	IFA (brain)	No
Visvesvara et al. (1990) [87]	72 M	Chronic renal failure	Deceased	IFA (brain)	No
Visvesvara et al. (1990) [87]	0 y 9 mo F	Diarrhea, cough, fever, cranial nerve palsy	Deceased	IFA (brain)	No
Visvesvara et al. (1990) [87]	61 M	Altered mental status, prior skin lesion(s)	Deceased	IFA (brain)	No

Table 2 (continued)

Publication [References #]	Demographics (age in years, gender)	Clinical presentation	Outcome	Method of diagnosis	Diagnosed by plasma mNGS
Vsvesvara et al. (1990) [87]	22 M	Head injury, headache, seizure	Deceased	IFA (brain)	No
Vsvesvara et al. (1990) [87]	11 F	Seizure, headache, fever, vomiting	Deceased	IFA (brain)	No
Vsvesvara et al. (1990) [87]	39 M	Seizure, cranial nerve deficits, coma	Deceased	IFA (brain)	No
Vsvesvara et al. (1990) [87]	22 M	Headache, seizure, nasal mass	Deceased	IFA (brain)	No
Vsvesvara et al. (1990) [87]	30 M	Headache, nausea, emesis, dizziness, diplopia	Deceased	IFA (brain)	No
Vsvesvara et al. (1990) [87]	60 M	Skin lesion(s)	Deceased	IFA (brain)	No
Vsvesvara et al. (1990) [87]	60 M	Seizure, hemiparesis	Deceased	IFA (brain)	No

blood. We identified 20 cases reporting positive *B. mandrillaris* mNGS testing results, with 6 positive tests performed on brain tissue, 14 on CSF, 2 on plasma, 1 on serum, and 1 that did not identify the specimen (see Table 2), with some testing more than one tissue type. One report identified *B. mandrillaris* using mNGS on serum, also with positive mNGS on CSF and brain [59]. One case reported negative mNGS on CSF in the setting of positive mNGS on brain biopsy in a patient who survived [105]. Our analysis found only two other reported instance of *B. mandrillaris* detected via plasma mNGS. In both of those cases, CSF was also positive via mNGS and/or PCR [36, 120]. In contrast, in our case, plasma mNGS successfully identified the pathogen, while CSF *B. mandrillaris* PCR and CSF mNGS were both reported negative.

Upon retrospective review of the CSF mNGS raw data for this case, two reads mapping to *B. mandrillaris* were identified—far below the assay's reporting threshold of 50 reads. PCR on this sample was also negative. Our observation of subthreshold reads highlights the challenges of interpreting mNGS data and may reflect several factors, including pathogen distribution between compartments and timing of sample collections. We note that CSF was collected 7 days prior to plasma and thus mNGS of CSF sampled concurrently with plasma may have yielded a positive result. While mNGS of CSF shows utility for many organisms, its sensitivity for *B. mandrillaris* is unknown. A comprehensive study of nearly 5,000 CSF mNGS results from patients with suspected CNS infections detected subthreshold *B. mandrillaris* reads in CSF in 2 of 3 identified cases [104]. Detection of *B. mandrillaris* DNA in plasma but not in CSF raises plasma mNGS as a possible diagnostic tool if CSF testing is inconclusive. However, the sensitivity and specificity of plasma mNGS for the diagnosis of *B. mandrillaris* GAE are not established. In the absence of these data, results should be interpreted with caution. Diagnostic laboratories offering mNGS testing on CSF could potentially consider reporting rare and difficult-to-diagnose pathogens like *B. mandrillaris* even if below the usual threshold for reporting.

Abbreviations

AFB	Acid-Fast Bacilli
<i>B. mandrillaris</i>	<i>Balamuthia mandrillaris</i>
CD	Cluster of Differentiation
CNS	Central Nervous System
Cp	Crossing Point (used in PCR)
CSF	Cerebrospinal Fluid
DNA	Deoxyribonucleic Acid
ELISA	Enzyme-linked immunosorbent assay
FFPE	Formalin-Fixed, Paraffin-Embedded
GAE	Granulomatous Amoebic Encephalitis
GMS	Gomori Methenamine Silver
H&E	Hematoxylin and Eosin
HBMECs	Human Brain Microvascular Endothelial Cells
IFA	Immunofluorescence Assay

IHC	Immunohistochemistry
mNGS	Metagenomic Next-Generation Sequencing
MRI	Magnetic Resonance Imaging
PAS	Periodic Acid-Schiff
PCR	Polymerase Chain Reaction
qPCR	Real-time Polymerase Chain Reaction

Acknowledgements

We thank the patient's clinical team, including Hannah Breit, Grace Kuo, and Olga Manouvakova.

Author contributions

S.Y.E., A.H., and S.B.W. wrote the main manuscript text. S.Y.E and A.H. prepared all figures and Table 2. R.W.R and A.H. prepared Table 1. R.W.R., A.P.N., K.M.H., and D.C. edited the manuscript text. A.P.N. also performed the free-living amoeba PCR and interpretation. M.S.S. provided radiologic interpretation. C.K. and J.H.B. performed the autopsy. A.J.M. and K.M.H. provided surgical biopsy interpretation. All authors reviewed the manuscript.

Funding

No external funding was received for this study.

Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Informed consent for publication was obtained from the patient's next of kin.

Competing interests

The authors declare that they have no competing interests.

Received: 12 February 2025 Accepted: 16 February 2025

Published online: 13 March 2025

References

1. Ai J, Zhang H, Yu S, Li J, Chen S, Zhang W, Mao R (2022) A case of fatal amoebic encephalitis caused by *Balamuthia mandrillaris*, China. Infect Genet Evol 97:105190. <https://doi.org/10.1016/j.meegid.2021.105190>
2. Anzil AP, Rao C, Wrzolek MA, Visvesvara GS, Sher JH, Kozlowski PB (1991) Amoebic meningoencephalitis in a patient with AIDS caused by a newly recognized opportunistic pathogen. Leptomyxid ameba Arch Pathol Lab Med 115(1):21–25
3. Aoki R, Sakakima T, Ohashi A, Niwa R, Matsuyama M, Etori F, Watanabe N, Yagita K, Tanaka T (2020) A Japanese case of amoebic meningoencephalitis initially diagnosed by cerebrospinal fluid cytology. Clin Case Rep 8(9):1728–1734. <https://doi.org/10.1002/ccr3.2953>
4. Bakardjiev A, Azimi PH, Ashouri N, Ascher DP, Janner D, Schuster FL, Visvesvara GS, Glaser C (2003) Amoebic encephalitis caused by *Balamuthia mandrillaris*: report of four cases. Pediatr Infect Dis J 22(5):447–453. <https://doi.org/10.1097/01.inf.0000066540.18671.f8>
5. Cary LC, Maul E, Potter C, Wong P, Nelson PT, Given C 2nd, Robertson W Jr (2010) *Balamuthia mandrillaris* meningoencephalitis: survival of a pediatric patient. Pediatrics 125(3):e699–703. <https://doi.org/10.1542/peds.2009-1797>
6. Centers for Disease Control and Prevention (CDC) (2010) *Balamuthia mandrillaris* transmitted through organ transplantation—Mississippi, 2009. MMWR Morb Mortal Wkly Rep 59(36):1165–1170
7. Centers for Disease Control and Prevention (CDC) (2010) Notes from the field: transplant-transmitted *Balamuthia mandrillaris*—Arizona, 2010. MMWR Morb Mortal Wkly Rep 59(36):1182

8. Centers for Disease Control and Prevention. About *Balamuthia* Infections. <https://www.cdc.gov/balamuthia/about/index.html>. Accessed January 15, 2025.
9. Chang OH, Liu F, Knopp E, Muehlenbachs A, Cope JR, Ali I, Thompson R, George E (2016) Centrofacial Balamuthiasis: case report of a rare cutaneous amebic infection. *J Cutan Pathol* 43(10):892–897. <https://doi.org/10.1111/cup.12748>
10. Chimelli L, Hahn MD, Scaravilli F, Wallace S, Visvesvara GS (1992) Granulomatous amoebic encephalitis due to leptomyxid amoebae: report of the first Brazilian case. *Trans R Soc Trop Med Hyg* 86(6):635. [https://doi.org/10.1016/0035-9203\(92\)90164-8](https://doi.org/10.1016/0035-9203(92)90164-8)
11. Cope JR et al (2019) The epidemiology and clinical features of *Balamuthia mandrillaris* disease in the United States, 1974–2016. *Clin Infect Dis*. <https://doi.org/10.1093/cid/ciy813>
12. Cope JR, Murphy J, Kahler A, Gorbett DG, Ali I, Taylor B, Corbitt L, Roy S, Lee N, Roellig D, Brewer S, Hill VR (2018) Primary amebic meningoencephalitis associated with rafting on an artificial whitewater river: case report and environmental investigation. *Clin Infect Dis* 66(4):548–553. <https://doi.org/10.1093/cid/cix101>
13. Cuevas PM, Smoje PG, Jofré ML, Ledermann DW, Noemí HI, Berwart CF, Latorre LJJ, González BS (2006) Meningoencefalitis granulomatosa por *Balamuthia mandrillaris*: reporte de un caso y revisión de la literatura [Granulomatous amoebic meningoencephalitis by *Balamuthia mandrillaris*: case report and literature review]. *Rev Chilena Infectol* 23(3):237–242. <https://doi.org/10.4067/s0716-10182006000300007>
14. Cuoco JA, Klein BJ, LeBel DP, Faulhaber J, Apfel LS, Witcher MR (2022) Successful treatment of a *Balamuthia mandrillaris* cerebral abscess in a pediatric patient with complete surgical resection and antimicrobial therapy. *Pediatr Infect Dis J* 41(2):e54–e57. <https://doi.org/10.1097/INF.0000000000003418>
15. Deetz TR, Sawyer MH, Billman G, Schuster FL, Visvesvara GS (2003) Successful treatment of *Balamuthia* amoebic encephalitis: presentation of 2 cases. *Clin Infect Dis* 37(10):1304–1312. <https://doi.org/10.1086/379020>
16. Denney CF, Iragui VJ, Uber-Zak LD, Karpinski NC, Ziegler EJ, Visvesvara GS, Reed SL (1997) Amebic meningoencephalitis caused by *Balamuthia mandrillaris*: case report and review. *Clin Infect Dis* 25(6):1354–1358. <https://doi.org/10.1086/516141>
17. Deol I, Robledo L, Meza A, Visvesvara GS, Andrews RJ (2000) Encephalitis due to a free-living amoeba (*Balamuthia mandrillaris*): case report with literature review. *Surg Neurol* 53(6):611–616. [https://doi.org/10.1016/s0090-3019\(00\)00232-9](https://doi.org/10.1016/s0090-3019(00)00232-9)
18. Doyle JS, Campbell E, Fuller A, Spelman DW, Cameron R, Malham G, Gin D, Lewin SR (2011) *Balamuthia mandrillaris* brain abscess successfully treated with complete surgical excision and prolonged combination antimicrobial therapy. *J Neurosurg* 114(2):458–462. <https://doi.org/10.3171/2010.10.JNS10677>
19. Duke BJ, Tyson RW, DeBiasi R, Freeman JE, Winston KR (1997) *Balamuthia mandrillaris* meningoencephalitis presenting with acute hydrocephalus. *Pediatr Neurosurg* 26(2):107–111. <https://doi.org/10.1159/0000121172>
20. Fan X, Chen T, Yang H, Gao Y, Chen Y (2023) Encephalomyelomeningitis caused by *Balamuthia mandrillaris*: a case report and literature review. *Infect Drug Resist* 2(16):727–733. <https://doi.org/10.2147/IDR.S400692>
21. Galarza M, Cuccia V, Sosa FP, Monges JA (2002) Pediatric granulomatous cerebral amebiasis: a delayed diagnosis. *Pediatr Neurol* 26(2):153–156. [https://doi.org/10.1016/s0887-8994\(01\)00360-5](https://doi.org/10.1016/s0887-8994(01)00360-5)
22. González-Alfonzo JE, Martínez AJ, García V, García-Tamayo J, Céspedes G (1991) Granulomatous encephalitis due to a leptomyxid amoeba. *Trans R Soc Trop Med Hyg* 85(4):480. [https://doi.org/10.1016/0035-9203\(91\)90227-p](https://doi.org/10.1016/0035-9203(91)90227-p)
23. Gordon SM, Steinberg JP, DuPuis MH, Kozarsky PE, Nickerson JF, Visvesvara GS (1992) Culture isolation of Acanthamoeba species and leptomyxid amoebas from patients with amebic meningoencephalitis, including two patients with AIDS. *Clin Infect Dis* 15(6):1024–1030. <https://doi.org/10.1093/clind/15.6.1024>
24. Gramp PE, Dooley J, O'Brien B, Jones A, Tan L, Robson J, Robertson T, Simos P, Fuller R, Gramp DV, Meumann EM (2023) Fatal granulomatous amebic encephalitis initially presenting with a cutaneous lesion. *Australas J Dermatol* 64(3):e256–e261. <https://doi.org/10.1111/ajd.14068>
25. Greninger AL, Messacar K, Dunnebacke T et al (2015) Clinical metagenomic identification of *Balamuthia mandrillaris* encephalitis and assembly of the draft genome: the continuing case for reference genome sequencing. *Genome Med* 7:113. <https://doi.org/10.1186/s13073-015-0235-2>
26. Griesemer DA, Barton LL, Reese CM, Johnson PC, Gabrielsen JA, Talwar D, Visvesvara GS (1994) Amebic meningoencephalitis caused by *Balamuthia mandrillaris*. *Pediatr Neurol* 10(3):249–254. [https://doi.org/10.1016/0887-8994\(94\)90034-5](https://doi.org/10.1016/0887-8994(94)90034-5)
27. Heilmann A et al (2024) Impact of climate change on amoeba and the bacteria they host. *J Assoc Med Microbiol Infect Dis Can*. <https://doi.org/10.3138/jammi-2023-09-08>
28. Hill CP, Damodaran O, Walsh P, Jevon GP, Blyth CC (2011) Balamuthia amebic meningoencephalitis and mycotic aneurysms in an infant. *Pediatr Neurol* 45(1):45–48. <https://doi.org/10.1016/j.pediatrneurol.2011.05.003>
29. Hirakata S, Sakiyama Y, Yoshimura A, Ikeda M, Takahata K, Tashiro Y, Yoshimura M, Arata H, Yonezawa H, Kirishima M, Higashi M, Hatanaka M, Kanekura T, Yagita K, Matsuuwa E, Takashima H (2021) The application of shotgun metagenomics to the diagnosis of granulomatous amoebic encephalitis due to *Balamuthia mandrillaris*: a case report. *BMC Neurol* 21(1):392. <https://doi.org/10.1186/s12883-021-02418-y>
30. Hu J, Zhang Y, Yu Y, Yu H, Guo S, Shi D, He J, Hu C, Yang J, Fang X, Xiao Y (2022) Encephalomyelitis caused by *Balamuthia mandrillaris* in a woman with breast cancer: a case report and review of the literature. *Front Immunol* 5(12):768065. <https://doi.org/10.3389/fimmu.2021.768065>
31. Intalapaporn P, Suankratay C, Shuangshoti S, Phantumchinda K, Keelawat S, Wilde H (2004) *Balamuthia mandrillaris* meningoencephalitis: the first case in southeast Asia. *Am J Trop Med Hyg* 70(6):666–669
32. Itoh K, Yagita K, Nozaki T, Katano H, Hasegawa H, Matsuo K, Hosokawa Y, Tando S, Fushiki S (2015) An autopsy case of *Balamuthia mandrillaris* amoebic encephalitis, a rare emerging infectious disease, with a brief review of the cases reported in Japan. *Neuropathology* 35(1):64–69. <https://doi.org/10.1111/neup.12151>
33. Javed Z, Hussain MM, Ghanchi Nil, Gilani A, Enam SA (2024) Non-granulomatous meningoencephalitis with *Balamuthia mandrillaris* mimicking a tumor: first confirmed case from Pakistan. *Surg Neurol Int* 12(15):238. https://doi.org/10.2529/SNI_181_2024
34. Joo SJ, Thompson AB, Philipsborn R, Emrath E, Camacho-Gonzalez AF, Chahroudji A, Miller J, Ali I, Cope J (2018) An unusual cause of fever and headache in a school-aged male. *Clin Pediatr (Phila)* 57(11):1359–1362. <https://doi.org/10.1177/009922818772056>
35. Jung S, Schelper RL, Visvesvara GS, Chang HT (2004) *Balamuthia mandrillaris* meningoencephalitis in an immunocompetent patient: an unusual clinical course and a favorable outcome. *Arch Pathol Lab Med* 128(4):466–468. <https://doi.org/10.5858/2004-128-466-BMMIAI>
36. Kalyatanda G, Rand K, Lindner MS, Hong DK, Sait Albayram M, Gregory J, Kresak J, Ibne KMA, Cope JR, Roy S, Gary JM, Reddy V, Ahmed AA (2020) Rapid, noninvasive diagnosis of *Balamuthia mandrillaris* encephalitis by a plasma-based next-generation sequencing test. *Open Forum Infect Dis* 7(7):ofaa89. <https://doi.org/10.1093/ofid/ofaa189>
37. Kansagra AP, Menon JP, Yarbrough CK, Urbanik A, Waters JD, Borys E, Jandial R (2009) *Balamuthia mandrillaris* meningoencephalitis in an immunocompromised patient. Case report. *J Neurosurg* 111(2):301–305. <https://doi.org/10.3171/2008.9.JNS08718>
38. Katz JD, Ropper AH, Adelman L, Worthington M, Wade P (2000) A case of *Balamuthia mandrillaris* meningoencephalitis. *Arch Neurol* 57(8):1210–1212. <https://doi.org/10.1001/archneur.57.8.1210>
39. Khurana S, Hallur V, Goyal MK, Sehgal R, Radotra BD (2015) Emergence of *Balamuthia mandrillaris* meningoencephalitis in India. *Indian J Med Microbiol* 33(2):298–300. <https://doi.org/10.4103/0255-0857.154887>
40. Kobayashi S, Tsukadaira A, Kobayashi S, Izumiya S, Yoon HS (2015) Amebic encephalitis in a farmer. *Pathology* 47(7):720–722. <https://doi.org/10.1097/PAT.0000000000000331>
41. Kodet R, Nohýnková E, Tichý M, Soukup J, Visvesvara GS (1998) Amebic encephalitis caused by *Balamuthia mandrillaris* in a Czech child: description of the first case from Europe. *Pathol Res Pract* 194(6):423–429. [https://doi.org/10.1016/S0344-0338\(98\)80033-2](https://doi.org/10.1016/S0344-0338(98)80033-2)
42. Krasaelap A, Prechawit S, Chansaenroj J, Punyahotra P, Puthanakit T, Chomtho K, Shuangshoti S, Amornfa J, Poovorawan Y (2013) Fatal

- Balamuthia amebic encephalitis in a healthy child: a case report with review of survival cases. *Korean J Parasitol* 51(3):335–341. <https://doi.org/10.3347/kjp.2013.51.3.335>
43. Lee DC, Fiester SE, Madeline LA, Fulcher JW, Ward ME, Schammel CM, Hakimi RK (2020) *Acanthamoeba* spp. and *Balamuthia mandrillaris* leading to fatal granulomatous amebic encephalitis. *Forensic Sci Med Pathol* 16(1):171–176. <https://doi.org/10.1007/s12024-019-00202-6>
 44. Lee JY, Yu IK, Kim SM, Kim JH, Kim HY (2021) Fulminant disseminating fatal granulomatous amebic encephalitis: the first case report in an immunocompetent patient in South Korea. *Yonsei Med J* 62(6):563–567. <https://doi.org/10.3349/ymj.2021.62.6.563>
 45. Li Q, Yang XH, Qian J (2005) September 2004: a 6-year-old girl with headache and stiff neck. *Brain Pathol* 15(1):93–95. <https://doi.org/10.1111/j.1750-3639.2005.tb00109.x>
 46. Li Z, Li W, Li Y, Ma F, Li G (2024) A case report of *Balamuthia mandrillaris* encephalitis. *Heliyon* 10(5):e26905. <https://doi.org/10.1016/j.heliyon.2024.e26905>
 47. Liu J, Zhang W, Wu S, Zeng T, Luo F, Jiang Q, Yang R (2023) A clinical case report of Balamuthia granulomatous amoebic encephalitis in a non-immunocompromised patient and literature review. *BMC Infect Dis* 23(1):245. <https://doi.org/10.1186/s12879-023-08228-6>
 48. Lobo SA, Patil K, Jain S, Marks S, Visvesvara GS, Tenner M, Braun A, Wang G, El Khoury MY (2013) Diagnostic challenges in *Balamuthia mandrillaris* infections. *Parasitol Res* 112(12):4015–4019. <https://doi.org/10.1007/s00436-013-3592-z>
 49. Lowichik A, Rollins N, Delgado R, Visvesvara GS, Burns DK (1995) Leptomyxid amebic meningoencephalitis mimicking brain stem glioma. *AJNR Am J Neuroradiol* 16(4):926–929
 50. Maehara T, Mizuno T, Tokoro M, Hara T, Tomita Y, Makioka K, Motegi SI, Yamazaki A, Matsumura N, Nobusawa S, Yokoo H (2022) An autopsy case of granulomatous amebic encephalitis caused by *Balamuthia mandrillaris* involving prior amebic dermatitis. *Neuropathology* 42(3):190–196. <https://doi.org/10.1111/neup.12798>
 51. Mani V, Hudgins E (2021) *Balamuthia mandrillaris* encephalitis in an uncontrolled diabetic patient. *IDCases* 8(25):e01174. <https://doi.org/10.1016/j.idcr.2021.e01174>
 52. Martínez AJ, Guerra AE, García-Tamayo J, Céspedes G, González-Alfonzo JE, Visvesvara GS (1994) Granulomatous amebic encephalitis: a review and report of a spontaneous case from Venezuela. *Acta Neuropathol* 87(4):430–434. <https://doi.org/10.1007/BF00313614>
 53. Matin A, Siddiqui R, Jung SY et al (2007) *Balamuthia mandrillaris* interactions with human brain microvascular endothelial cells in vitro. *J Med Microbiol* 56:1110–1115. <https://doi.org/10.1099/jmm.0.47134-0>
 54. Mittal SO, Alsinaidi O (2017) Teaching neuroimages: *Balamuthia mandrillaris* amebic encephalitis: clinical-radiologic-pathologic correlation. *Neurology* 88(18):e183. <https://doi.org/10.1212/WNL.00000000000003891>
 55. Neafie RC, Marty AM (1993) Unusual infections in humans. *Clin Microbiol Rev* 6(1):34–56. <https://doi.org/10.1128/CMR.6.1.34>
 56. Ono Y, Higashida K, Yamanouchi K, Nomura S, Hanamatsu Y, Saigo C, Tetsuka N, Shimohata T (2024) *Balamuthia mandrillaris* amoebic encephalitis mimicking tuberculous meningitis. *Neuropathology* 44(1):68–75. <https://doi.org/10.1111/neup.12932>
 57. Orozco LD, Khan MA, Fratkin JD, Hanigan WC (2011) Asymptomatic aneurysm of the cavernous and supraclinoid internal carotid artery in a patient with *Balamuthia mandrillaris* encephalitis. *J Clin Neurosci* 18(8):1118–1120. <https://doi.org/10.1016/j.jocn.2010.11.033>
 58. Pan D, Bridges LR, du Parcq J, Mahadeva U, Roy S, Ali IKM, Cosgrove CA, Chiodini PL, Zhang L (2020) A rare cause of left-sided weakness in an elderly woman: amoebic encephalitis. *Lancet* 396(10244):e1. [https://doi.org/10.1016/S0140-6736\(20\)31365-9](https://doi.org/10.1016/S0140-6736(20)31365-9)
 59. Peng L, Zhou Q, Wu Y, Cao X, Lv Z, Su M, Yu Y, Huang W (2022) A patient with granulomatous amoebic encephalitis caused by *Balamuthia mandrillaris* survived with two excisions and medication. *BMC Infect Dis* 22(1):54. <https://doi.org/10.1186/s12879-021-07020-8>
 60. Perez MT, Bush LM (2007) Fatal amebic encephalitis caused by *Balamuthia mandrillaris* in an immunocompetent host: a clinicopathological review of pathogenic free-living amebae in human hosts. *Ann Diagn Pathol* 11(6):440–447. <https://doi.org/10.1016/j.anndiagpath.2006.04.003>
 61. Phillips BC, Gokden M, Petersen E (2013) Granulomatous encephalitis due to *Balamuthia mandrillaris* is not limited to immune-compromised patients. *Clin Neurol Neurosurg* 115(7):1102–1104. <https://doi.org/10.1016/j.clineuro.2012.08.015>
 62. Piper MJ, Foster H, Susanto D, Maree CL, Thornton SD, Cobbs CS (2018) Fatal *Balamuthia mandrillaris* brain infection associated with improper nasal lavage. *Int J Infect Dis* 77:18–22. <https://doi.org/10.1016/j.ijid.2018.09.013>
 63. Popek EJ, Neafie RC (1992) Granulomatous meningoencephalitis due to leptomyxid ameba. *Pediatr Pathol* 12(6):871–881. <https://doi.org/10.3109/15513819209024246>
 64. Pritzker AS, Kim BK, Agrawal D, Southern PM Jr, Pandya AG (2004) Fatal granulomatous amebic encephalitis caused by *Balamuthia mandrillaris* presenting as a skin lesion. *J Am Acad Dermatol* 50(2):S38–41. [https://doi.org/10.1016/s0190-9622\(03\)02090-5](https://doi.org/10.1016/s0190-9622(03)02090-5)
 65. Qin L, Xiang Y, Wu Z, Zhang H, Wu X, Chen Q (2024) Metagenomic next-generation sequencing for diagnosis of fatal Balamuthia amoebic encephalitis. *Infect Genet Evol* 119:105570. <https://doi.org/10.1016/j.meegid.2024.105570>
 66. Qin S, Lu X, Li L, Huang D (2024) Nursing care in intensive care unit of a patient infected with *Balamuthia mandrillaris* after renal transplantation: a case report. *Transplant Proc* 56(5):1183–1187. <https://doi.org/10.1016/j.transproceed.2024.02.019>
 67. Reed RP, Cooke-Yarborough CM, Jaquiere AL, Grimwood K, Kemp AS, Su JC, Forsyth JR (1997) Fatal granulomatous amoebic encephalitis caused by *Balamuthia mandrillaris*. *Med J Aust* 167(2):82–84. <https://doi.org/10.5694/j.1326-5377.1997.tb138785.x>
 68. Rowen JL, Doerr CA, Vogel H, Baker CJ (1995) *Balamuthia mandrillaris*: a newly recognized agent for amebic meningoencephalitis. *Pediatr Infect Dis J* 14(8):705–710
 69. Roy SL, Atkins JT, Gennuso R, Kofos D, Sriram RR, Dorlo TP, Hayes T, Qvarnstrom Y, Kucerova Z, Guglielmo BJ, Visvesvara GS (2015) Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual *Balamuthia mandrillaris* strain. *Parasitol Res* 114(12):4431–4439. <https://doi.org/10.1007/s00436-015-4684-8>
 70. Safavi M, Mehrashvili V, Habibi Z, Mohammadpour M, Hagh Ashtiani MT, Sotoudeh Anvari M, Zaresharifi N, Shafizadeh M, Jafarzadeh B (2021) Case report: encephalitis caused by *Balamuthia mandrillaris* in a 3-year-old Iranian girl. *Am J Trop Med Hyg* 104(5):1836–1840. <https://doi.org/10.4299/ajtmh.20-1257>
 71. Sakusic A, Chen B, McPhearson K, Badi M, Freeman WD, Huang JF, Siegel JL, Jentoft ME, Oring JM, Verdecia J, Meschia JF (2023) *Balamuthia mandrillaris* encephalitis presenting as a symptomatic focal hypodensity in an immunocompromised patient. *Open Forum Infect Dis* 10(3):094. <https://doi.org/10.1093/ofid/ofad094>
 72. Schafer KR, Shah N, Almira-Suarez ML, Reese JM, Hoke GM, Mandell JW, Roy SL, Visvesvara G (2015) Disseminated *Balamuthia mandrillaris* infection. *J Clin Microbiol* 53(9):3072–3076. <https://doi.org/10.1128/JCM.01549-15>
 73. Schuster FL, Dunnebacke TH, Booton GC, Yagi S, Kohlmeier CK, Glaser C, Vugia D, Bakardjiev A, Azimi P, Maddux-Gonzalez M, Martinez AJ, Visvesvara GS (2003) Environmental isolation of *Balamuthia mandrillaris* associated with a case of amebic encephalitis. *J Clin Microbiol* 41(7):3175–3180. <https://doi.org/10.1128/JCM.41.7.3175-3180.2003>
 74. Shirabe T, Monobe Y, Visvesvara GS (2002) An autopsy case of amebic meningoencephalitis. the first Japanese case caused by *Balamuthia mandrillaris*. *Neuropathology* 22(3):213–217. <https://doi.org/10.1046/j.1440-1789.2002.00444.x>
 75. Silva RA, Araújo Sde A, Avellar IF, Pittella JE, Oliveira JT (2010) Granulomatous amoebic meningoencephalitis in an immunocompetent patient. *Arch Neurol* 67(12):1516–1520. <https://doi.org/10.1001/archneurol.2010.309>
 76. Silva-Vergara ML, Da Cunha Colombo ER, De Figueiredo VE, Silva AC, Chica JE, Etchebehere RM, Adad SJ (2007) Disseminated *Balamuthia mandrillaris* amoeba infection in an AIDS patient from Brazil. *Am J Trop Med Hyg* 77(6):1096–1098
 77. Stidd DA, Root B, Weinand ME, Anton R (2012) Granulomatous amoebic encephalitis caused by *Balamuthia mandrillaris* in an immunocompetent girl. *World Neurosurg* 78(6):715.e7–12. <https://doi.org/10.1016/j.wneu.2011.10.040>

78. Suyo-Prieto F, Núñez J, Guzmán K, Mostajo F, de Amat F, Ruiz M, Postigo M, Cabello-Vilchez AM (2021) Primer informe clínico de *Balamuthia mandrillaris* en el distrito de Camaná, Arequipa, Perú [First case report of the *Balamuthia mandrillaris* in the Camaná district of Arequipa, Peru]. Rev Argent Microbiol 53(2):129–134. <https://doi.org/10.1016/j.ram.2020.05.002>
79. Suzuki T, Okamoto K, Genkai N, Kakita A, Abe H (2020) A homogeneously enhancing mass evolving into multiple hemorrhagic and necrotic lesions in amoebic encephalitis with necrotizing vasculitis. Clin Imaging 60(1):48–52. <https://doi.org/10.1016/j.clinimag.2019.10.015>
80. Szymanski KA, Kuwabara MS, Friedman N, Pfeifer CM (2024) A devastating case of a *Balamuthia mandrillaris* pediatric brain infection. Radiol Case Rep 19(9):3648–3652. <https://doi.org/10.1016/j.radcr.2024.05.056>
81. Takei K, Toyoshima M, Nakamura M, Sato M, Shimizu H, Inoue C, Shimizu Y, Yagita K (2018) An acute case of granulomatous amoebic Encephalitis-*Balamuthia mandrillaris* Infection. Intern Med 57(9):1313–1316. <https://doi.org/10.2169/internalmedicine.0011-17>
82. Tarai B, Agarwal P, Krishnamoorthi S, Mewara A, Khurana S (2018) Fatal Amoebic Meningoencephalitis caused by *Balamuthia mandrillaris* in a sarcoidosis patient. Jpn J Infect Dis 71(6):474–476. <https://doi.org/10.7883/yoken.JJD.2018.179>
83. Taratuto AL, Monges J, Acefe JC, Meli F, Paredes A, Martinez AJ (1991) Leptomyxid amoeba encephalitis: report of the first case in Argentina. Trans R Soc Trop Med Hyg 85(1):77. [https://doi.org/10.1016/0035-9203\(91\)90164-t](https://doi.org/10.1016/0035-9203(91)90164-t)
84. Tavares M, Correia da Costa JM, Carpenter SS, Santos LA, Afonso C, Aguiar A, Pereira J, Cardoso AI, Schuster FL, Yagi S, Sriram R, Visvesvara GS (2006) Diagnosis of first case of *Balamuthia* amoebic encephalitis in Portugal by immunofluorescence and PCR. J Clin Microbiol 44(7):2660–2663. <https://doi.org/10.1128/JCM.00479-06>
85. Tootla HD, Eley BS, Enslin JMN, Frean JA, Hlela C, Kilborn TN, Moodley B, Peer S, Singh S, Nuttall JJC (2022) *Balamuthia mandrillaris* granulomatous amoebic encephalitis: the first African experience. J Pediatric Infect Dis Soc 11(2):578–581. <https://doi.org/10.1093/jpids/piac096>
86. van der Beek NA, van Tienen C, de Haan JE, Roelfsema J, Wismans PJ, van Genderen PJ, Tanghe HL, Verdijk RM, Titulaer MJ, van Hellemond JJ (2015) Fatal *Balamuthia mandrillaris* Meningoencephalitis in the Netherlands after Travel to The Gambia. Emerg Infect Dis 21(5):896–898. <https://doi.org/10.3201/eid2105.141325>
87. Visvesvara GS, Martinez AJ, Schuster FL, Leitch GJ, Wallace SV, Sawyer TK, Anderson M (1990) Leptomyxid ameba, a new agent of amoebic meningoencephalitis in humans and animals. J Clin Microbiol 28(12):2750–2756. <https://doi.org/10.1128/jcm.28.12.2750-2756.1990>
88. Vollmer ME, Glaser C (2016) A *Balamuthia* survivor. JMM Case Rep 3(3):e005031. <https://doi.org/10.1099/jmmcr.0.005031>
89. Wang L, Li B, Zhao T, Wang L, Jian Z, Cheng W, Chen J, Li C, Wang G, Gao T (2022) Treatment of cutaneous *Balamuthia mandrillaris* infection with diminazene aceturate: a report of 4 cases. Clin Infect Dis 75(9):1637–1640. <https://doi.org/10.1093/cid/ciac356>
90. Wang WN, Liang YM, Wang YN, Zhang S (2024) *Balamuthia mandrillaris* amoebic encephalitis: report of a case. Zhonghua Bing Li Xue Za Zhi 53(12):1284–1286. <https://doi.org/10.3760/cmaj.cn112151-2024-531-00356>
91. White JM, Barker RD, Salisbury JR, Fife AJ, Lucas SB, Warhurst DC, Higgins EM (2004) Granulomatous amoebic encephalitis. Lancet 364(9429):220. [https://doi.org/10.1016/S0140-6736\(04\)16640-3](https://doi.org/10.1016/S0140-6736(04)16640-3)
92. Wilson MR, Shambhag NM, Reid MJ, Singhal NS, Gelfand JM, Sample HA, Benkli B, O'Donovan BD, Ali IK, Keating MK, Dunnebacke TH, Wood MD, Bollen A, DeRisi JL (2015) Diagnosing *Balamuthia mandrillaris* encephalitis with metagenomic deep sequencing. Ann Neurol 78(5):722–730. <https://doi.org/10.1002/ana.24499>
93. Wu X, Yan G, Han S, Ye Y, Cheng X, Gong H, Yu H (2020) Diagnosing *Balamuthia mandrillaris* encephalitis via next-generation sequencing in a 13-year-old girl. Emerg Microbes Infect 9(1):1379–1387. <https://doi.org/10.1080/22221751.2020.1775130>
94. Xu H, Wang D, Cui K, Wan R, Chi Q, Wu T (2024) 18F-FDG PET/CT findings in fatal *Balamuthia mandrillaris* encephalitis in brain stem: a case report. Radiol Case Rep 19(5):1851–1854. <https://doi.org/10.1016/j.radcr.2024.02.021>
95. Yamasaki K, Sugimoto T, Futami M, Moriyama T, Uehara H, Takeshima H, Moriguchi S, Marutsuka K, Asada Y (2011) Granulomatous amoebic encephalitis caused by *Balamuthia mandrillaris*. Neurol Med Chir (Tokyo) 51(9):667–670. <https://doi.org/10.2176/nmc.51.667>
96. Yang Y, Hu X, Min L, Dong X, Guan Y (2020) *Balamuthia mandrillaris*-related primary amoebic encephalitis in China diagnosed by next generation sequencing and a review of the literature. Lab Med 51(2):e20–e26. <https://doi.org/10.1093/labmed/lmz079>
97. Yao S, Chen X, Qian L, Sun S, Zhao C, Bai Z, Chen Z, Wu Y (2023) Diagnosing *Balamuthia mandrillaris* amoebic meningoencephalitis in a 64-year-old woman from the Southwest of China. Parasites Hosts Dis 61(2):183–193. <https://doi.org/10.3347/PHD.23039>
98. Yi Z, Zhong J, Wu H, Li X, Chen Y, Chen H, Yang Y, Yu X (2021) *Balamuthia mandrillaris* encephalitis in a child: case report and literature review. Diagn Microbiol Infect Dis 100(4):115180. <https://doi.org/10.1016/j.diagmicrobio.2020.115180>
99. Yohannan B, Feldman M (2019) Fatal *Balamuthia mandrillaris* encephalitis. Case Rep Infect Dis 31(2019):9315756. <https://doi.org/10.1155/2019/9315756>
100. Zagardo MT, Castellani RJ, Zoarski GH, Bauserman SC (1997) Granulomatous amoebic encephalitis caused by leptomyxid amebae in an HIV-infected patient. AJNR Am J Neuroradiol 18(5):903–908
101. Zhang Z, Liang J, Wei R, Feng X, Wang L, Wang L, Zhao P, Yu H, Gu Y, Yao Z (2022) Facial *Balamuthia mandrillaris* infection with neurological involvement in an immunocompetent child. Lancet Infect Dis 22(3):e93–e100. [https://doi.org/10.1016/S1473-3099\(21\)00334-0](https://doi.org/10.1016/S1473-3099(21)00334-0)
102. Zheng Z, Chen F, Qin L, Lu A, Xu H, Zhao M, Zhao Y (2024) Application of ventriculoscopy in granulomatous amoebic encephalitis: a case report in China and literature review. Front Med (Lausanne) 20(11):1431225. <https://doi.org/10.3389/fmed.2024.1431225>
103. Zwillich M, Nguyen AT, Organek N, Kobiessi ZA, Kodali S, Immanuel KE (2021) Rapid cerebral edema and herniation in a 65-year-old man with *Balamuthia mandrillaris*. Cureus 13(4):e14498. <https://doi.org/10.7759/cureus.14498>
104. Benoit P, Brazer N, de Lorenzi-Tognon M et al (2024) Seven-year performance of a clinical metagenomic next-generation sequencing test for diagnosis of central nervous system infections. Nat Med 30:3522–3533. <https://doi.org/10.1038/s41591-024-03275-1>
105. Spottswoode N, Pet D, Kim A, Gruenberg K, Shah M, Ramachandran A, Laurie MT, Zia M, Fouassier C, Boutilier CL, Lu R, Zhang Y, Servellita V, Bollen A, Chiu CY, Wilson MR, Valdivia L, DeRisi JL (2023) Successful treatment of *Balamuthia mandrillaris* granulomatous amoebic encephalitis with nitroxoline. Emerg Infect Dis 29(1):197–201. <https://doi.org/10.3201/eid2901.221531>
106. Levinson S, Kumar KK, Wang H, Tayyar R, Dunning M, Toland A, Budyytiene I, Vogel H, Chang A, Banaei N, Shuer L (2022) *Balamuthia mandrillaris* brain infection: a rare cause of a ring-enhancing central nervous system lesion. Illustrative case J Neurosurg Case Lessons 3(15):CASE2268. <https://doi.org/10.3171/CASE2268>
107. Prasad K, Bhatia R, Srivastava MV, Pardasani V, Garg A, Rishi A (2008) Fatal subacute necrotising brainstem encephalitis in a young man due to a rare parasitic (*Balamuthia*) infection. Pract Neurol 8(2):112–117. <https://doi.org/10.1136/jnpn.2007.142547>
108. Xu C, Wu X, Tan M, Wang D, Wang S, Wu Y (2022) Subacute *Balamuthia mandrillaris* encephalitis in an immunocompetent patient diagnosed by next-generation sequencing. J Int Med Res 50(5):3000605221093217. <https://doi.org/10.1177/03000605221093217>
109. Saffiotti C, Mesini A, Caorsi R, Severino M, Gattorno M, Castagnola E (2022) *Balamuthia mandrillaris* infection: report of 1st autochthonous, fatal case in Italy. Eur J Clin Microbiol Infect Dis 41(4):685–687. <https://doi.org/10.1007/s10096-022-04404-9>
110. Kum SJ, Lee HW, Jung HR, Choe M, Kim SP (2019) Amoebic encephalitis caused by *Balamuthia mandrillaris*. J Pathol Transl Med 53(5):327–331. <https://doi.org/10.4132/jptm.2019.05.14>
111. Lehmer LM, Ulibarri GE, Ragsdale BD, Kunkle J (2017) Cutaneous *Balamuthia mandrillaris* infection as a precursor to *Balamuthia* amoebic encephalitis (BAE) in a healthy 84-year-old Californian. Dermatol Online J 23(7):13030
112. Shehab KW, Aboul-Nasr K, Elliott SP (2018) *Balamuthia mandrillaris* granulomatous amoebic encephalitis with renal dissemination in a previously healthy child: case report and review of the pediatric literature. J Pediatric Infect Dis Soc 7(3):e163–e168. <https://doi.org/10.1093/jpids/pix089>

113. Ott A, Hoppenbouwers WJ, Wisselink G, Wolffhagen MJ, Sijbrandij ES, Elshoff JC (2015) Fatale encefalitis door een parasiet [Fatal encephalitis caused by a parasite]. *Ned Tijdschr Geneeskd* 159:A8187
114. Pindyck TN, Dvorscak LE, Hart BL, Palestine MD, Gallant JE, Allen SE, SantaCruz KS (2014) Fatal Granulomatous Amoebic Encephalitis Due to *Balamuthia mandrillaris* in New Mexico: A Case Report. *Open Forum Infect Dis* 1(2):ofu062. <https://doi.org/10.1093/ofu/ofu062>
115. Greninger AL, Messacar K, Dunnebacke T, Naccache SN, Federman S, Bouquet J, Mirsky D, Nomura Y, Yagi S, Glaser C, Vollmer M, Press CA, Kleinschmidt-DeMasters BK, Dominguez SR, Chiu CY (2015) Clinical metagenomic identification of *Balamuthia mandrillaris* encephalitis and assembly of the draft genome: the continuing case for reference genome sequencing. *Genome Med* 1(7):113. <https://doi.org/10.1186/s13073-015-0235-2>. (Erratum. In: *Genome Med*. 2016 Jan 11;8(1):1. doi:10.1186/s13073-015-0257-9. Kleinschmidt-DeMasters, BetteK [corrected to Kleinschmidt-DeMasters, BetteK]. PMID:26620704; PMCID: PMC4665321)
116. Hara T, Yagita K, Sugita Y (2019) Pathogenic free-living amoebic encephalitis in Japan. *Neuropathology* 39(4):251–258. <https://doi.org/10.1111/neup.12582>
117. Moriarty P, Burke C, McCrossin D, Campbell R, Cherian S, Shahab MS, Visvesvara GS, Nourse C (2014) *Balamuthia mandrillaris* encephalitis: survival of a child with severe meningoencephalitis and review of the literature. *J Pediatric Infect Dis Soc* 3(1):e4–9. <https://doi.org/10.1093/jpids/pit033>
118. Kato H, Mitake S, Yuasa H, Hayashi S, Hara T, Matsukawa N (2013) Successful treatment of granulomatous amoebic encephalitis with combination antimicrobial therapy. *Intern Med* 52(17):1977–1981. <https://doi.org/10.2169/internalmedicine.52.0299>
119. Xiong Y, Lou X (2025) *Balamuthia mandrillaris* encephalitis post-raw beef ingestion. *Ann Neurol* 97(2):384–385. <https://doi.org/10.1002/ana.27082>
120. Aboubechara JP, Kantamneni T, Pasao K (2024) *Balamuthia mandrillaris* central nervous system vasculitis in an immunocompetent child: case report. *J Child Neurol* 19:8830738241307058. <https://doi.org/10.1177/08830738241307058>
121. Guarner J, Bartlett J, Shieh WJ, Paddock CD, Visvesvara GS, Zaki SR (2007) Histopathologic spectrum and immunohistochemical diagnosis of amoebic meningoencephalitis. *Mod Pathol* 20(12):1230–1237. <https://doi.org/10.1038/modpathol.3800973>
122. Recavarren-Arce S, Velarde C, Gotuzzo E, Cabrera J (1999) Amoeba angeitic lesions of the central nervous system in *Balamuthia mandrillaris* amoebiasis. *Hum Pathol* 30(3):269–273. [https://doi.org/10.1016/s0046-8177\(99\)90004-7](https://doi.org/10.1016/s0046-8177(99)90004-7)

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.